anticoagulants, antiplatelet, thrombolytics Flashcards
UFH uses
rapid parenteral anticoagulation
UFH mechanism
w/antithrombin III binds and inactivates clotting factors II, X, IX, XII, kallikrein
intrinsic and common pathways
UFH route of administration
IV, SQ
UFH monitor tests
aPTT 1.5-2.5x control
thrombin time
high doses elevated PT
UFH most notable side effect
bleeding, thrombocytopenia
UFH indications
UA/NSTEMI AMI PCI VTE prevention and treatment DIC
low MW heparin
parenteral, prophylaxis, and treatment of MI, DVT, and PE
mechanism of low MW heparin
binds antithrombin inhibits X
route of administration low MW heparin
SQ
Monitor testsing low MW heparin
testing not usually necessary
low MW heparin side effect
bleeding
indications for low MW heparin
UA/NSTEMI AMI PCI VTE prevention and treatment
warfarin uses
slow sustained oral anticoagulant
warfarin mechanism
inhibits vit K dependent clotting factors II, VII, IX, X, protein C and S
extrinsic and common
warfarin administration
PO
warfarin monitor tests
PT -> INR (2-3)
warfarin side effects
bleeding
drug-drug interactions
warfarin indications
VTE
AFib
LMWHs
Enoxaparin
-parin
factor X inhibitors
fondaparinux
rivoxaban
apixban
dabigatran uses
oral anticoagulant
prevention of stroke in non-valvular afib
prevention of stroke in knee and hip replacements
dabigatran mechansims
binds directly to thrombin, inhibits clot bound circulationg thrombin, decrease thrombin stimulated platelet aggregation
dabigatran monitor testing
none
dabigatran side effects
bleeding < warfarin
dyspepsia, gastritis, GI bleeding
very expensive
rivaroxaban uses
oral anticoagulant
prevention of DVT in patients w/knee and hip replacement
prevention of stroke and DVT in non-valvular afib
rivaroxaban mechanisms
binds directly to and inhibits Xa
monitor testing rivaroxaban
none
rivaroxaban side effects
bleeding >/= enoxaparin
expensive
apixaban uses
oral anticoagulant
prevention of stroke and systemic embolism in non-valvular aFib
aspirin mechanism
inhibits TXA2 formation blocking platelet aggregation
aspirin indications
prophaylaxis and treatment of MI, stroke, PAD
Clopidogrel mechanism
blocks platelet aggregation by blocking P2Y12 ADPR
clopidogrel indications
prophylaxis of stroke, MI, PAD, and ACS
prasugrel mechanism
irreversibly binds P2Y12 ADPR inhbits platelet aggregation
prasugrel indications
prophylaxis of thrombotic CV events in patients w/ACS being managed w/PCI
dipyridamole mechanisms
blocks platelet aggregation inhibits adenosine uptake and cAMP phosphodiesterase inhibitor
dypyridamole indications
prophylaxis of thromboembolism
ticlopidine mechanisms
blocks platelet aggregation by blocKing P2Y12 ADPR
ticlopidine indications
prophylaxis of recurrent stroke, thrombosis during stent placement,
adverse die effects limit use
cilostazol mechanism
blocks platelet aggregation causes vasodilation
cilostaxol indications
intermittent claudication
PAD
pentoxifylline mechanisms
hemorheologic agent
improves blood flow
pentoxifylline indicatios
intermittent claudication of limbs
PAD
efficacy questionable
antiplatlet drugs
aspirin clopidogrel prasugrel sipyridamole ticlopidine cilostazol pentoxifylline
GPIIb/IIIa inhibitors
abciximab
eptifibatide
tirofiban
abciximab mechanism
monoclonal Ab vs glycoprotein IIb/IIIa complex
epitfibatide and tirofiban mechanism
block fibrinogen binding to IIb/IIIa complex
indications for GPIIb/IIIa inhibitors
acute coroary syndromes during percutaneous coronayr intervention (PIC)/angioplasty
direct thrombin inhibitors
lepirudin
bivalirudin
argatroban
lepirudin mechanism
direct binding to thrombin
lepirudin indications
Tx of heparin induced thrombocytopenia (HIT)
bivalirudin mechanisms
direct binding to thrombin
bivalirudin indications
percutaneous coronary angioplasty
argatroban mechanism
direct binding to thrombin
argatroban indications
HIT
thrombolytic drugs summary
alteplase
reteplase
tenecteplase
streptokinase
alteplase mechanism
activator of plasminogen
alteplase
AMI PE arterial thrombosis non-hemorrhagic ischemic stroke DVT
reteplase mechanism
activator of plasminogen
reteplase indications
AMI
coronary artery thrombosis
tenecteplase mechanism
activator of plasminogen
tenecteplase indications
AMI
streptokinase mechanism
nonenzymatic activaotr of plasminogen
stimulated dissolution of fibrin clots
streptokinase indications
AMI
PE
DVT
arterial thrombosis
heparin effects on clotting tests
prolongs both aPTT and thrombin time
at high plasma concentrations will also prolong PT
HIT
heparin induced thrombocytopenia
up to 25% of patients
due to formation of Abs directed against heparin -> Ab-Ag complexes -> paradoxical thrombosis-> treated w/direct thrombin inhibitors
treatment for heparin overdose
protamine sulfate
strongly basic protein administered IV binds and inactivated heparin b/c of strong + charge
fondaparinux
synthetic analog of heparin
factor X inactivation
does not cause HIT
does not affect PT, aPTT, bleeding time, or platelet fnx
indicated in DCT after fracture or surgery
warfarin pharmacokinetics
onset delayed 36-72 hours
99% bound to albumin
termination delayed due to long half life 40hours
contraindication of warfarin
pregnancy bleeding unreliable patient severe HTN suspected aneurysm
ticopodine adverse effects
life-threatening rxns neutropenia/agranulocytosis TTP aplastic anemia should only be used in patients intolerant or allergic to aspirin or clopidogrel
aPTT
intrinsic pathway
hemophilias
used to monitor UFH
PT
should be 12-14 seconds
IRN normalizes result and used to monitor warfarin
thrombin itime
if long may be due to increased antithrombin